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Abstract 
Background: Patients suffering from migraine or tension-type headache (TTH) often treat their complaints with 
over-the-counter (OTC) medications. Fixed dose combinations of acetylsalicylic acid, paracetamol and caffeine (APC) 
are among the most commonly used analgesics, and their efficacy for treating acute headache pain has been well 
demonstrated. This investigation was run to better characterize patients who treat their headache with OTC APC com-
binations, as well as treatment effects.
Methods: A pharmacy-based patient survey in 164 German pharmacies was performed. Patients (age ≥18 years) 
who purchased APC analgesics (of the brand Thomapyrin®) were handed a questionnaire, which had to be filled out 
at patients own discretion after taking the medication. Demographics, pain characteristics and perceived efficacy and 
tolerability data were analysed with descriptive statistics.
Results: Questionnaires from 1298 patients were analysed, of whom 71.9 % were females and 28.1 % were males. 
Headache patients were assigned to TTH or migraine according to diagnosis criteria of the International Headache 
Classification-II (ICHD-II), with 828 patients for TTH and 206 for migraine. About one third of patients in the subgroup 
migraine did not report their pain as migraine. Nausea, photophobia/phonophobia turned out to be the most distin-
guishing feature between migraine and TTH. The main reasons for purchasing the product were recommendation by 
the pharmacists (40.5 %) and/or friends or relatives (24.4 %). 74 % of TTH and 55 % of migraine patients reported onset 
of pain relief within the first 30 min. More than 90 % rated efficacy as well as tolerability to be “good” or “very good”.
Conclusions: The main reason for purchasing APC products in the pharmacy are TTH or migraine. About a third 
of patients fulfilling the IHCD-II criteria for migraine failed to recognize their headache as migraine. This could be 
explained e.g. by patients’ misconceptions about their pain. Patients’ assessments of efficacy and tolerability showed 
that the investigated APC combinations are valuable for the treatment of TTH and migraine headache. These data 
complement those of randomized clinical studies on such preparations.
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Background
Fixed dose combinations of acetylsalicylic acid, paraceta-
mol and caffeine are in widespread use for the treatment 
of episodic headaches. Typical over-the-counter (OTC) 
products contain 250  mg acetylsalicylic acid, 200 or 
250 mg paracetamol and 50 mg caffeine per tablet (APC 
combination), with the recommended dose of one to two 
tablets every 4–8 h up to six tablets daily.
APC combinations are among the best investigated 
analgesics for the treatment of acute headaches in self-
medication. In all controlled, randomized, placebo-con-
trolled studies performed so far, this triple combination 
showed statistically significant and clinically relevant 
superiority over comparators, among them the mono-
compounds acetylsalicylic acid, paracetamol, and ibupro-
fen, when used with the maximum recommended OTC 
dose, as well as the prescription-only migraine medica-
tion sumatriptan (Laska et al. 1983, 1984; Migliardi et al. 
1994; Lipton et  al. 1998; Diener et  al. 2005; Goldstein 
et al. 2005, 2006). A meta-analysis of RCTs demonstrated 
the benefit of the APC combination for patients with 
episodic TTH even in those with pain rated severe. The 
combination was superior to placebo, as well as to par-
acetamol for the endpoints pain-free at 2  h, headache 
response at 2  h, and ability to return to daily activities 
(Diener et  al. 2014). According to the evidence-based 
therapeutic guideline, the APC combination is a first-line 
treatment for the self-medication of episodic migraine 
and TTH (with “highlighted recommendation on the 
basis of the analysed comparative studies”), recom-
mended by the German Neurological Society, as well as 
the headache societies in Germany, Austria and Switzer-
land (Haag et al. 2011).
This pharmacy-based patient survey collected data 
regarding the usage of two APC preparations in self-
diagnosing and self-treating patients under daily life con-
ditions. The aim of the study was to extend the current 
knowledge about characteristics of patients, their pain 
and pain treatment, as well as efficacy and tolerability of 
these fixed combination analgesics.
Methods
This prospective, non-interventional survey was run 
in 164 German pharmacies between October 2013 
and March 2014. Patients who purchased Thomapy-
rin® CLASSIC or Thomapyrin® INTENSIV [containing 
250 mg acetylsalicylic acid, 200 (“CLASSIC”) or 250 mg 
paracetamol (“INTENSIV”) and 50 mg caffeine per tab-
let] and consented to participate were handed a ques-
tionnaire, which had to be filled out at patients own 
discretion after taking the medication, preferably on the 
same day. Patients were asked to send the completed 
questionnaire to the institute that analysed the data 
(Winicker Norimed GmbH, Germany) in a sealed enve-
lope. Personal data enabling to identify a patient were not 
collected. Thus no formal ethical approval was necessary.
Preconditions for participation comprised age 
≥18 years, purchase of one of the both APC medications 
for treatment of headache or any other pain, willingness 
and ability to independent, plausible and timely com-
pletion of the questionnaire. No exclusion criteria were 
defined.
The paper based questionnaire obtained—among oth-
ers—information on sex, age, height, weight, frequency 
of pain within last 30 days, limitation of daily activity by 
pain (within the last 30 days), and reasons for purchasing 
this products.
Parameters related to last pain episode provoking the 
intake of the drug: first usage (yes/no), type of pain (head-
ache, migraine, other), intensity of pain (numeric rat-
ing scale; scale of 0–10), time of pain event, time of first 
usage of the drug after onset of pain event; if applicable: 
time of repeated usage, time to onset of pain relief, sub-
ject’s assessment of efficacy, subject’s assessment of toler-
ability, willingness to recommend usage of Thomapyrin® 
to others.
The characterization of a subject’s type of headache 
pain was based on the diagnostic criteria of the Inter-
national Classification of Headache Disorders (ICHD-
II, 2004), i.e. pain location [one-sided (1a), both-sided 
or diffuse (1b)]; pain characteristics [throbbing (2a), 
pressing/tightening (2b)]; whether pain increased due 
to physical strain [yes (3a), no (3b)]; occurrence of the 
accompanying symptoms nausea, photophobia or pho-
nophobia [yes (4a), no (4b)]. A subject was assigned to 
subgroup “migraine” if (1a AND 2a AND 4a) or (1a AND 
3a AND 4a) or (2a AND 3a AND 4a) were met. A subject 
was assigned to subgroup “TTH” if [1b AND 2b AND (3b 
OR 4b)] or (2b AND 3b AND 4b) or (1b AND 3b AND 
4b) were met. Moreover, patients were asked to assign 
their headache to “migraine” or “headache” (i.e. all other 
non-migraine headaches). A subject was assigned to the 
subgroup “other”, if the subject’s diagnosis of “type of 
pain” was “other”. In case a subject could not be assigned 
unambiguously to any subgroup, the subject was omitted 
from the analyses pertaining to this subgroup.
Safety
Any adverse drug reaction arising out of completed ques-
tionnaires had to be reported by the institute that col-
lected and analysed the data to Boehringer Ingelheim and 
was processed accordingly.
Data analysis
Data management and statistical analysis were performed 
using SAS, Version 9.2. As appropriate for the design of 
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the study, only descriptive analyses and statistical mod-
elling were performed. Numerical data were compared 
exploratively between subgroups using a Wilcoxon or 
Kruskal–Wallis test. Analyses were done for the total 
study population and for study subgroups separately.
Results
Study population
A total of 1302 patients completed the questionnaire. The 
data from four patients were excluded from the analysis, 
because three of them had no documented intake of the 
product, and one did not report the type of pain treated. 
Thus, the data of 1298 patients were available for the 
analysis. A summary of the main demographic variables 
is provided in Table 1.
Pain anamnesis
A total of 1284 patients reported a mean of 5.4 ± 5.5 days 
with any kind of pain during the last 30  days. Female 
patients reported overall more days with pain than males 
[5.6 ± 5.7 (n = 921) vs. 4.8 ± 5.0 (n = 362); p = 0.002]. 
Migraine patients reported more days with pain than 
TTH patients [6.7 ± 6.0 (n = 204) vs. 4.8 ± 5.0 (n = 818); 
p < 0.001].
Information on the number of days (during the last 
30  day interval) where activities of daily living could 
not be performed due to pain was obtained from 1057 
patients. In total, a mean of 1.5 ± 3.2 days was reported. 
Females reported slightly more days than male patients 
[1.6 ± 3.3 (n = 751) vs. 1.3 ± 2.9 (n = 305); p = 0.025], 
and migraine patients more than TTH patients [2.5 ± 3.6 
(n = 206) vs. 1.1 ± 2.8 (n = 828); p = <0.001].
Mean baseline pain intensity before the intake of the 
medication was 5.9  ±  1.7. Migraine patients reported 
more severe pain (6.8 ± 1.6; n = 204) than TTH patients 
(5.6 ± 1.7; n = 824; p < 0.001); no difference in baseline 
pain between male and female patients was found.
Based on requested information about the last episode 
of headache, 828 patients fulfilled the IHCD-II criteria 
for TTH. 760 patients (91.8 %) of them documented non-
migraine headache themselves, while 12 patients (1.4 %) 
documented migraine. The remaining 56 patients (6.8 %) 
did not clearly allocate their headache pain to one spe-
cific type.
A total of 206 patients were attributed to migraine. 111 
patients (53.9 %) of them diagnosed migraine themselves, 
while 61 patients (29.6  %) documented non-migraine 
headache. The remaining 34 patients (16.5  %) did not 
clearly allocate their headache pain to one specific type. 
Thus, about one third of the patients fulfilling the IHCD-
II criteria for migraine did not recognize their pain as 
migraine.
Thirty patients among all reported to suffer from 
migraine and non-migraine headache. The acute episode 
of nine of them (30.0 %) was assigned to TTH, 21 of them 
(70.0 %) to migraine.
The pain characteristics are shown in Table  2. These 
data show that e.g. 26.5 % of patients with migraine felt 
the pain to be “pressing/tightening”, and the same per-
centage of patients with TTH reported it to be “throb-
bing”. 91.2 % of patients with migraine versus 53.0 % with 
TTH reported increasing pain during physical strain. 
Nausea, photophobia/phonophobia were present in 
95.6 % of patients with migraine (versus 10.4 % in TTH), 
and therefore turned out to be the most distinguishing 
feature between migraine and TTH.
Surveyed treatment
The reasons for buying the medication are shown in 
Table  3. In the majority of cases recommendations (by 
pharmacists, relatives or friends) triggered the purchase 
decision.
The median time between occurrence of the pain epi-
sode and intake of the medication was 45 min (n = 942), 
with no difference between male and female patients. 
However, migraine patients took the medication ear-
lier than those suffering from TTH [median 30  min for 
migraine (n  =  153) vs. 45  min for headache (n  =  594) 
vs. 105 min for other pain (n = 163); p < 0.001]. Patients 
who took the APC combination for the first time waited 
longer than those who already knew the product [median 
of 90  min (n  =  287) for first-time users vs. 35  min 
(n = 646) for experienced users; p < 0.001].
The mean dose at first intake was 1.4 ± 0.5 tablets, with 
a mean total of 1.8 ± 1.2 tablets for the entire pain event. 
The mean dose was slightly higher for migraine versus 
TTH patients (1.5 ± 0.6; n = 179 vs. 1.3 ± 0.5; n = 706; 
Table 1 Demographics
Sex
 Male [n (%)] 365 (28.1)
 Female [n (%)] 932 (71.9)
Age (years)
 Mean ± SD 39.2 ± 14.1
 Median (range) 36 (16–88)
Height (cm)
 Mean ± SD 171.1 ± 9.2
 Median (range) 170 (147–203)
Weight (kg)
 Mean ± SD 71.7 ± 14.9
 Median (range) 69 (42–140)
BMI (kg/m2)
 Mean ± SD 24.4 ± 4.0
 Median (range) 23.7 (14.9–47.3)
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p < 0.001). Higher percentages of migraine patients took 
more than one dose during the pain episode (migraine: 
59.8 % one, 24.6 % two, and 15.6 % three doses compared 
to 82.0, 12.7 and 5.4 % for TTH, p < 0.001). Consequently, 
the mean total number of tablets per pain episode was 
also higher for migraine patients [2.3 ± 1.4 (n = 206) for 
migraine vs. 1.6 ± 1.0 (n = 710) for TTH; p < 0.001].
Parameters of efficacy
Fast onset of action of an analgesic is desired by patients 
and contributes to the overall impression of efficacy 
(Pageler et  al. 2009). Onset of pain relief as reported 
by the patients was different for TTH and migraine 
(p  <  0.001; Fig.  1a, b): e.g. 74  % of the TTH patients 
reported onset of pain relief within 30  min after intake 
of the medication, compared to 55  % of the migraine 
patients. Also previous experience with the medication, 
compared to first time usage, affected the perceived time 
to onset of action (p < 0.001; Fig. 1c, d). The same per-
centage of patients report onset of pain relief within the 
first 30 min after intake (70  %), however, a higher per-
centage of first-time users perceived pain relief within the 
first 15 min after intake (32 vs. 20 %).
The overall patient-reported assessment of efficacy 
was rather positive. TTH patients rated efficacy slightly 
higher than migraine patients (97 vs. 93 % “good” or “very 
good”, respectively; p = 0.048; Fig. 2a, b).
Patients taking the APC combination for the first time 
rated efficacy slightly less positive, compared to patients 
who already had experience with the medication (90 vs. 
97 % “good” or “very good”; p < 0.001; Fig. 2c, d).
Tolerability and adverse events
Overall tolerability was rated by 95  % of the patients 
as “good” or “very good”. No relevant differences were 
reported for TTH versus migraine (96 vs. 94 % “good” or 
“very good”; p = 0.34, Fig. 3a, b), as well as for first time 
compared to experienced users (96 vs. 95  % “good” or 
“very good”; p = 0.022; Fig. 3c, d).
No serious adverse drug reactions were reported dur-
ing this survey. 95  % of the 143 adverse event reports 
stated intake of Thomapyrin® INTENSIV for treating 
other than headache or migraine pain. Since in Germany 
the product is placed on the market solely for sympto-
matic treatment of headache or migraine (different from 
Thomapyrin® CLASSIC), these reports were addressed 
as off-label use. Poor efficacy was reported by the 
remaining 5  %. In summary, no new safety information 
was retrieved from the survey.
Table 2 Pain characteristics/symptoms
Headache (N = 828) n (%) Migraine (N = 206) n (%) p value
Location of pain
 One-sided 195 (23.8 %) 141 (68.4 %) <0.001
 Bilateral 351 (42.9 %) 39 (18.9 %)
 Diffuse, assignment of side not possible 273 (33.3 %) 26 (12.6 %)
 Missing values 9 –
Pain characteristics
 Throbbing 217 (26.5 %) 145 (71.1 %) <0.001
 Pressing/tightening 595 (72.6 %) 54 (26.5 %)
 Both 7 (0.9 %) 5 (2.5 %)
 Missing values 9 2
Increasing pain during physical strain
 No 383 (47.0 %) 18 (8.8 %) <0.001
 Yes 432 (53.0 %) 187 (91.2 %)
 Missing values 13 1
Nausea/photophobia/phonophobia present?
 No 733 (89.6 %) 9 (4.4 %) <0.001
 Yes 85 (10.4 %) 196 (95.6 %)
 Missing values 10 1
Table 3 Reasons for purchasing the medication
Recommended by pharmacist 526 (40.5 %)
Recommended by relative/friend 317 (24.4 %)
Known from advertising 295 (22.7 %)
Other 276 (21.3 %)
Recommended by physician 36 (2.8 %)
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Discussion
Pharmacy-based patient surveys are valuable tools to 
gain information on patient demographic and character-
istics of the treated complaints, as well as on the effects of 
investigated treatments as assessed by the patient. Espe-
cially in the context of OTC treatment, such surveys can 
provide insights which are otherwise hard to obtain and 
complement those of controlled clinical trials (Nieber 
and Lehmacher 2009).
Patient characteristics/study population
This study investigated patients treating acute pain with 
two OTC available APC combination analgesics. The 
overall prevalence of headache is high (Pfaffenrath et al. 
2009), and, therefore, it was not surprising that most of 
the patients reported headache or migraine as treated ail-
ment (83 % in total). In line with published data, women 
are more frequently affected by headache and migraine, 
compared to men. Not unexpectedly, patients suffer-
ing from migraine reported more severe pain and more 
days with impairment of daily activities than headache 
patients.
Pain anamnesis
In this survey, patients were asked to categorize their 
pain (as “headache”, “migraine”, or “other pain”). In addi-
tion, patients were asked to describe their headache char-
acteristics according to ICHD-II in order to discriminate 
between TTH and migraine, and their personal assess-
ment was compared to diagnoses according to ICHD-II 
(see Table  2). This analysis showed some discrepancies. 
Notable, only 68  % of patients with migraine reported 
unilateral pain. On the other hand, 26 % of the patients 
with TTH reported their pain to be throbbing. Other 
characteristics, however, appeared to be more specific. 
Nausea, photophobia or phonophobia were only reported 
by 10 % of those suffering from TTH, but by 96 % of the 
patients with migraine. Based on the data obtained in this 
study, it cannot be concluded whether patients treating 
their headaches with OTC analgesics are not sufficiently 
educated to judge migraine from TTH, or whether the 
extensive symptom overlap might have caused the diffi-
culties in differentiating both types of headache. This is 
in line with data from a study which analysed diagnosis 
at first attendance in Italian headache centres, where only 































































































































Fig. 1 Time to onset of pain relief after intake of the APC combination. a, b Show the data for TTH and migraine patients. In both patient groups 
the majority reported onset of pain relief within 30 min. A higher proportion of patients who used the APC combination for the first time (c) 
reported onset of pain relief within the first 15 min after intake, compared to experienced APC users (d). See text for details. Numbers of patients for 
the respective groups are given above the columns
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26.8 % of the migraine patients had the previous correct 
diagnosis of migraine (Cevoli et  al. 2009). Patient edu-
cation may be helpful for recognizing migraine attacks 
early by the patients themselves because early treatment 
(“treat when mild”) might improve treatment response 
(D’Amico et al. 2006; Gendolla 2008). Asking the patient 
about treatment response and modify acute treatment if 
necessary may prevent progression into chronic migraine 
over time (Lipton et al. 2015).
Treatment with the APC analgesic
The most prevalent reason for buying the APC product 
was recommendation by the pharmacist or friends/rela-
tives (Table  3). In 2.8  % of the cases, the analgesic was 
recommended by a physician. In the guideline of the Ger-
man, Austrian and Switzerland’s headache societies on 
the OTC treatment of episodic TTH and migraine, the 
APC combination was rated as “treatment of first choice”, 
and was the only analgesic obtaining a “highlighted rec-
ommendation on the basis of the analysed comparative 
studies” (Haag et  al. 2011). Thus, there appears to be a 
gap between the evidence-based treatment guideline and 
recommendation practice by pharmacists and physicians.
It can be hypothesized that the higher burden induced 
by migraine affected the medication use in this study: 
Compared to patients with TTH, those suffering from 
migraine reported higher baseline pain levels, took the 
first analgesic dose earlier, on average the first dose was 
higher, and the same held true for the total number of 
tablets taken per pain event. Onset of pain relief appeared 
to occur later (Fig. 1). On the other hand, the patient rat-
ings of efficacy did not reveal significant difference: More 
than 93  % of migraine patients rated the efficacy to be 
“good” or “very good”, compared to 97 % of patients with 
TTH (Fig. 2). Ratings for tolerability were similar for both 
patient groups (Fig. 3).
The results of open studies (like this survey) could 
be biased by patients’ expectations, as well as previous 
experience with the investigated medicinal products. 
In this survey, about 29  % of patients had no previous 













































































































































Fig. 2 Patients’ assessment of efficacy. Assessment of efficacy for patients using the APC combination for the treatment of TTH (a) or migraine (b), 
as well as for patients taking the medication for the first time (c), compared to experienced users (d). See text for details. Numbers of patients for the 
respective groups are given above the columns
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experience with the test products. A lower proportion of 
these patients reported pain relief within the first 15 min, 
but no relevant differences were observed after 30  min 
(Fig.  1). Assessment of efficacy was slightly in favour of 
patients with previous experience, but still 90  % of the 
APC-naive patients reported the efficacy to be “good” or 
“very good”, and assessment of tolerability was compara-
ble (Fig. 2).
Comparison with other investigations
Since pain is a highly individual experience, the patient 
assessment of efficacy (and tolerability) is a valuable 
measure of the individual treatment success of a given 
analgesic. Data from investigations on OTC doses of 
ibuprofen and acetylsalicylic acid for the treatment of 
migraine attacks with comparable methodology like this 
study have been reported. Here, 75.6 % of patients using 
ibuprofen to treat their migraine, and 76.8 % of patients 
using acetylsalicylic acid assessed the efficacy to be 
“good” or better (Goebel 2007; Krall 2007) compared to 
more than 90 % as reported in this study.
In two controlled clinical trials on treatment of acute 
migraine, 38.2 and 58.6  % patients taking ibuprofen 
reported “good” efficacy (Sandrini et  al. 1998; Diener 
et al. 2004a, b); for acetylsalicylic acid these figures were 
between 32.5 and 45.6 % (Lange et al. 2000; Diener et al. 
2004a, b). In the two trials on the APC combination 63 % 
of patients with migraine (Goldstein et al. 2005) and 73 % 
of patients with migraine or TTH (Diener et  al. 2005) 
reported efficacy to be “good” or better. In the latter study 
patients suffering from TTH as well as migraine were 
included, revealing only very small differences in efficacy 
between these types of headache (72.0 vs. 76.6 %, respec-
tively, data on file).
Thus, although methodologies of patient surveys and of 
controlled studies do differ, it appears that the (caffeine-
containing) APC combination offers clinical benefit to a 
higher number of patients. This conclusion is also sup-
ported by meta-analyses on caffeine as co-analgesic 
(Derry et al. 2014, 2015).
Conclusions
The main reason for purchasing APC products in the 
pharmacy are TTH or migraine. About a third of patients 
fulfilling the IHCD-II criteria for migraine failed to rec-
ognize their headache as migraine. This could be due to 
patients’ misconceptions about their pain, or the exten-
sive symptom overlap between migraine and TTH. 









































































































































Fig. 3 Patients’ assessment of tolerability. Assessment of tolerability for patients using the APC combination for the treatment of TTH (a) or migraine 
(b), as well as for patients taking the medication for the first time (c), compared to experienced users (d). See text for details. Numbers of patients for 
the respective groups are given above the columns
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Education of patients about their headache disorder 
might be a way to improve treatment of migraine and 
TTH in future. Patients’ assessments of efficacy and tol-
erability of the investigated APC combinations showed 
that the investigated APC combinations are beneficial for 
the treatment of TTH and migraine headache. These data 
complement those of randomized clinical studies on such 
preparations.
Taken together this study shows that pharmacy-based 
surveys can provide valuable data on patients and their 
ailments. Moreover, they can broaden our knowledge on 
treatment of these with OTC medicinal products, and 
provide information on the individual patient experi-
ences with the investigated medication.
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